The FDA has approved targeted therapy drugs for the treatment of some people with the following types of cancer. Some targeted therapy drugs are listed more than once because they have been approved to treat more than one type of cancer. The generic drug name is listed first, with a brand name in parentheses. If you can't find what you're looking for, contact us here.
Targeted therapy approved for brain cancer
belzutifan (Welireg)
bevacizumab (Avastin)
dabrafenib (Tafinlar)
everolimus (Afinitor)
tovorafenib (Ojemda)
trametinib (Mekinist)
vorasidenib (Voranigo)
Targeted therapy approved for breast cancer
abemaciclib (Verzenio)
ado-trastuzumab emtansine (Kadcyla)
alpelisib (Piqray)
anastrozole (Arimidex)
capivasertib (Truqap)
datopotamab deruxtecan-dlnk (Datroway)
elacestrant dihydrochloride (Orserdu)
everolimus (Afinitor)
exemestane (Aromasin)
fam-trastuzumab deruxtecan-nxki (Enhertu)
fulvestrant (Faslodex)
goserelin acetate (Zoladex)
inavolisib (Itovebi)
lapatinib ditosylate (Tykerb)
letrozole (Femara)
margetuximab-cmkb (Margenza)
neratinib maleate (Nerlynx)
olaparib (Lynparza)
palbociclib (Ibrance)
pembrolizumab (Keytruda)
pertuzumab (Perjeta)
pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo)
ribociclib (Kisqali)
ribociclib succinate and letrozole (Kisqali Femara Co-Pack)
sacituzumab govitecan-hziy (Trodelvy)
talazoparib tosylate (Talzenna)
tamoxifen citrate (Soltamox)
toremifene (Fareston)
trastuzumab (Herceptin)
tucatinib (Tukysa)
Targeted therapy approved for cervical cancer
bevacizumab (Avastin)
pembrolizumab (Keytruda)
tisotumab vedotin-tftv (Tivdak)
Targeted therapy approved for colorectal cancer
adagrasib (Krazati)
bevacizumab (Avastin)
cetuximab (Erbitux)
encorafenib (Braftovi)
fruquintinib (Fruzaqla)
ipilimumab (Yervoy)
nivolumab (Opdivo)
panitumumab (Vectibix)
pembrolizumab (Keytruda)
ramucirumab (Cyramza)
regorafenib (Stivarga)
sotorasib (Lumakras)
tucatinib (Tukysa)
ziv-aflibercept (Zaltrap)
Targeted therapy approved for dermatofibrosarcoma protuberans
imatinib mesylate (Gleevec)
Targeted therapy approved for endocrine and neuroendocrine tumors
avelumab (Bavencio)
everolimus (Afinitor)
iobenguane I 131 (Azedra)
lanreotide acetate (Somatuline Depot)
lutetium Lu 177-dotatate (Lutathera)
Targeted therapy approved for endometrial cancer
dostarlimab-gxly (Jemperli)
durvalumab (Imfinzi)
lenvatinib mesylate (Lenvima)
pembrolizumab (Keytruda)
Targeted therapy approved for esophageal cancer
fam-trastuzumab deruxtecan-nxki (Enhertu)
ipilimumab (Yervoy)
nivolumab (Opdivo)
pembrolizumab (Keytruda)
ramucirumab (Cyramza)
tislelizumab-jsgr (Tevimbra)
trastuzumab (Herceptin)
zolbetuximab-clzb (Vyloy)
Targeted therapy approved for head and neck cancer
cetuximab (Erbitux)
nivolumab (Opdivo)
pembrolizumab (Keytruda)
toripalimab-tpzi (Loqtorzi)
Targeted therapy approved for gastrointestinal stromal tumor
avapritinib (Ayvakit)
imatinib mesylate (Gleevec)
regorafenib (Stivarga)
ripretinib (Qinlock)
sunitinib malate (Sutent)
Targeted therapy approved for giant cell tumor
denosumab (Xgeva)
pexidartinib hydrochloride (Turalio)
Targeted therapy approved for kidney cancer
avelumab (Bavencio)
axitinib (Inlyta)
belzutifan (Welireg)
bevacizumab (Avastin)
cabozantinib-s-malate (Cabometyx)
everolimus (Afinitor)
ipilimumab (Yervoy)
lenvatinib mesylate (Lenvima)
nivolumab (Opdivo)
pazopanib hydrochloride (Votrient)
pembrolizumab (Keytruda)
sorafenib tosylate (Nexavar)
sunitinib malate (Sutent)
temsirolimus (Torisel)
tivozanib hydrochloride (Fotivda)
Targeted therapy approved for leukemia
acalabrutinib (Calquence)
alemtuzumab (Campath)
asciminib hydrochloride (Scemblix)
avapritinib (Ayvakit)
blinatumomab (Blincyto)
bosutinib (Bosulif)
brexucabtagene autoleucel (Tecartus)
dasatinib (Sprycel)
duvelisib (Copiktra)
enasidenib mesylate (Idhifa)
gemtuzumab ozogamicin (Mylotarg)
gilteritinib fumarate (Xospata)
glasdegib maleate (Daurismo)
ibrutinib (Imbruvica)
idelalisib (Zydelig)
imatinib mesylate (Gleevec)
inotuzumab ozogamicin (Besponsa)
ivosidenib (Tibsovo)
lisocabtagene maraleucel (Breyanzi)
midostaurin (Rydapt)
nilotinib (Tasigna)
obecabtagene autoleucel (Aucatzyl)
obinutuzumab (Gazyva)
ofatumumab (Arzerra)
olutasidenib (Rezlidhia)
pemigatinib (Pemazyre)
pirtobrutinib (Jaypirca)
ponatinib hydrochloride (Iclusig)
quizartinib dihydrochloride (Vanflyta)
revumenib citrate (Revuforj)
rituximab (Rituxan)
rituximab and hyaluronidase human (Rituxan Hycela)
tagraxofusp-erzs (Elzonris)
tisagenlecleucel (Kymriah)
tretinoin (Vesanoid)
venetoclax (Venclexta)
zanubrutinib (Brukinsa)
Targeted therapy approved for liver and bile duct cancer
atezolizumab (Tecentriq)
atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza)
bevacizumab (Avastin)
cabozantinib-s-malate (Cabometyx)
durvalumab (Imfinzi)
futibatinib (Lytgobi)
ipilimumab (Yervoy)
ivosidenib (Tibsovo)
lenvatinib mesylate (Lenvima)
nivolumab (Opdivo)
pembrolizumab (Keytruda)
pemigatinib (Pemazyre)
ramucirumab (Cyramza)
regorafenib (Stivarga)
sorafenib tosylate (Nexavar)
tremelimumab-actl (Imjudo)
zanidatamab-hrii (Ziihera)
Targeted therapy approved for lung cancer
adagrasib (Krazati)
afatinib dimaleate (Gilotrif)
alectinib (Alecensa)
amivantamab-vmjw (Rybrevant)
atezolizumab (Tecentriq)
atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza)
bevacizumab (Avastin)
binimetinib (Mektovi)
brigatinib (Alunbrig)
capmatinib hydrochloride (Tabrecta)
cemiplimab-rwlc (Libtayo)
ceritinib (Zykadia)
crizotinib (Xalkori)
dabrafenib mesylate (Tafinlar)
dacomitinib (Vizimpro)
durvalumab (Imfinzi)
encorafenib (Braftovi)
ensartinib hydrochloride (Ensacove)
Targeted therapy approved for lung cancer (cont'd)
entrectinib (Rozlytrek)
erlotinib hydrochloride (Tarceva)
fam-trastuzumab deruxtecan-nxki (Enhertu)
gefitinib (Iressa)
ipilimumab (Yervoy)
lazertinib mesylate hydrate (Lazcluze)
lorlatinib (Lorbrena)
necitumumab (Portrazza)
nivolumab (Opdivo)
osimertinib mesylate (Tagrisso)
pembrolizumab (Keytruda)
pralsetinib (Gavreto)
ramucirumab (Cyramza)
repotrectinib (Augtyro)
selpercatinib (Retevmo)
sotorasib (Lumakras)
tarlatamab-dlle (Imdelltra)
tepotinib hydrochloride (Tepmetko)
trametinib dimethyl sulfoxide (Mekinist)
tremelimumab-actl (Imjudo)
zenocutuzumab-zbco (Bizengri)
Targeted therapy approved for lymphoma
acalabrutinib maleate monohydrate (Calquence)
axicabtagene ciloleucel (Yescarta)
belinostat (Beleodaq)
bexarotene (Targretin)
bortezomib (Velcade)
brentuximab vedotin (Adcetris)
brexucabtagene autoleucel (Tecartus)
crizotinib (Xalkori)
denileukin diftitox-cxdl (Lymphir)
duvelisib (Copiktra)
epcoritamab-bysp (Epkinly)
glofitamab-gxbm (Columvi)
ibritumomab tiuxetan (Zevalin)
ibrutinib (Imbruvica)
lisocabtagene maraleucel (Breyanzi)
loncastuximab tesirine-lpyl (Zynlonta)
mogamulizumab-kpkc (Poteligeo)
mosunetuzumab-axgb (Lunsumio)
nivolumab (Opdivo)
obinutuzumab (Gazyva)
pembrolizumab (Keytruda)
pemigatinib (Pemazyre)
pirtobrutinib (Jaypirca)
polatuzumab vedotin-piiq (Polivy)
pralatrexate (Folotyn)
rituximab (Rituxan)
rituximab and hyaluronidase human (Rituxan Hycela)
romidepsin (Istodax)
selinexor (Xpovio)
siltuximab (Sylvant)
tafasitamab-cxix (Monjuvi)
tazemetostat hydrobromide (Tazverik)
tisagenlecleucel (Kymriah)
venetoclax (Venclexta)
vorinostat (Zolinza)
zanubrutinib (Brukinsa)
Targeted therapy approved for malignant mesothelioma
ipilimumab (Yervoy)
nivolumab (Opdivo)
pembrolizumab (Keytruda)
Targeted therapy approved for multiple myeloma
bortezomib (Velcade)
carfilzomib (Kyprolis)
ciltacabtagene autoleucel (Carvykti)
daratumumab (Darzalex)
daratumumab and hyaluronidase-fihj (Darzalex Faspro)
elranatamab-bcmm (Elrexfio)
elotuzumab (Empliciti)
idecabtagene vicleucel (Abecma)
isatuximab-irfc (Sarclisa)
ixazomib citrate (Ninlaro)
talquetamab-tgvs (Talvey)
selinexor (Xpovio)
teclistamab-cqyv (Tecvayli)
Targeted therapy approved for myelodysplastic and myeloproliferative disorders
fedratinib hydrochloride (Inrebic)
imatinib mesylate (Gleevec)
imetelstat sodium (Rytelo)
ivosidenib (Tibsovo)
momelotinib dihydrochloride monohydrate (Ojjaara)
pacritinib citrate (Vonjo)
pemigatinib (Pemazyre)
ruxolitinib phosphate (Jakafi)
Targeted therapy approved for neuroblastoma
dinutuximab (Unituxin)
naxitamab-gqgk (Danyelza)
Targeted therapy approved for ovarian epithelial, fallopian tube, and primary peritoneal cancers
bevacizumab (Avastin)
mirvetuximab soravtansine-gynx (Elahere)
niraparib tosylate monohydrate (Zejula)
olaparib (Lynparza)
rucaparib camsylate (Rubraca)
Targeted therapy approved for pancreatic cancer
belzutifan (Welireg)
erlotinib hydrochloride (Tarceva)
everolimus (Afinitor)
olaparib (Lynparza)
sunitinib malate (Sutent)
zenocutuzumab-zbco (Bizengri)
Targeted therapy approved for plexiform neurofibroma
selumetinib sulfate (Koselugo)
Targeted therapy approved for prostate cancer
abiraterone acetate (Zytiga)
apalutamide (Erleada)
bicalutamide (Casodex)
cabazitaxel (Jevtana)
darolutamide (Nubeqa)
degarelix (Firmagon)
enzalutamide (Xtandi)
flutamide
goserelin acetate (Zoladex)
leuprolide acetate (Lupron Depot, Eligard)
leuprolide mesylate (Camcevi)
lutetium Lu 177 vipivotide tetraxetan (Pluvicto)
nilutamide (Nilandron)
niraparib tosylate monohydrate and abiraterone acetate (Akeega)
olaparib (Lynparza)
talazoparib tosylate (Talzenna)
radium 223 dichloride (Xofigo)
relugolix (Orgovyx)
rucaparib camsylate (Rubraca)
triptorelin pamoate (Trelstar)
Targeted therapy approved for skin cancer
alitretinoin (Panretin)
atezolizumab (Tecentriq)
atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza)
avelumab (Bavencio)
binimetinib (Mektovi)
cemiplimab-rwlc (Libtayo)
cobimetinib fumarate (Cotellic)
cosibelimab-ipdl (Unloxcyt)
dabrafenib mesylate (Tafinlar)
encorafenib (Braftovi)
ipilimumab (Yervoy)
nivolumab (Opdivo)
nivolumab and relatlimab-rmbw (Opdualag)
pembrolizumab (Keytruda)
retifanlimab-dlwr (Zynyz)
sonidegib (Odomzo)
tebentafusp-tebn (Kimmtrak)
trametinib dimethyl sulfoxide (Mekinist)
vismodegib (Erivedge)
vemurafenib (Zelboraf)
Targeted therapy approved for soft tissue sarcoma
afamitresgene autoleucel (Tecelra)
alitretinoin (Panretin)
atezolizumab (Tecentriq)
atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza)
crizotinib (Xalkori)
nirogacestat hydrobromide (Ogsiveo)
pazopanib hydrochloride (Votrient)
sirolimus protein-bound particles (Fyarro)
tazemetostat hydrobromide (Tazverik)
Targeted therapy approved for solid tumors anywhere in the body
dabrafenib mesylate (Tafinlar)
dostarlimab-gxly (Jemperli)
entrectinib (Rozlytrek)
fam-trastuzumab deruxtecan-nxki (Enhertu)
larotrectinib sulfate (Vitrakvi)
pembrolizumab (Keytruda)
repotrectinib (Augtyro)
selpercatinib (Retevmo)
trametinib dimethyl sulfoxide (Mekinist)
Targeted therapy approved for stomach (gastric) cancer
fam-trastuzumab deruxtecan-nxki (Enhertu)
nivolumab (Opdivo)
pembrolizumab (Keytruda)
ramucirumab (Cyramza)
tislelizumab-jsgr (Tevimbra)
trastuzumab (Herceptin)
zolbetuximab-clzb (Vyloy)
Targeted therapy approved for systemic mastocytosis
avapritinib (Ayvakit)
imatinib mesylate (Gleevec)
midostaurin (Rydapt)
Targeted therapy approved for thyroid cancer
cabozantinib-s-malate (Cometriq)
dabrafenib mesylate (Tafinlar)
lenvatinib mesylate (Lenvima)
pralsetinib (Gavreto)
selpercatinib (Retevmo)
sorafenib tosylate (Nexavar)
trametinib dimethyl sulfoxide (Mekinist)
vandetanib (Caprelsa)
Find more information here.